Latest & greatest articles for famotidine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on famotidine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on famotidine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for famotidine

1. Famotidine

Famotidine Top results for famotidine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for famotidine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

2. Famotidine, a Histamine H (PubMed)

Famotidine, a Histamine H The neural mechanisms underlying levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) may involve histamine (H2) receptors on striatopallidal pathways. We recently demonstrated that the clinically available oral histamine H2 receptor antagonist (H2 RA), famotidine, can reduce l-dopa-induced chorea in MPTP-lesioned macaques. We hypothesized that famotidine may be useful in the treatment of LID in PD patients. We performed a proof-of-concept, double-blind (...) , randomized, multiple cross-over (4×) trial. Seven PD subjects with bothersome dyskinesia were randomized to oral famotidine 80, 120, and 160 mg/day and placebo. Each subject was randomized to receive each of the four treatment phases for 14 days followed by a 7-day wash-out period between each treatment phase. The primary outcome measure was change in the Unified Dyskinesia Rating Scale (UDysRS; part III) between placebo and famotidine. Secondary outcomes were UDysRS (parts I and II), Global Impression

Full Text available with Trip Pro

2014 Movement disorders clinical practice Controlled trial quality: predicted high

3. Randomised controlled trial: Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone

Randomised controlled trial: Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone

2013 Evidence-Based Medicine (Requires free registration)

4. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. (PubMed)

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. There are few therapeutic options for the prevention of gastrointestinal mucosal damage caused by low-dose aspirin. We therefore investigated the efficacy of famotidine, a well-tolerated histamine H(2)-receptor antagonist, in the prevention of peptic ulcers and erosive oesophagitis in patients receiving low-dose aspirin (...) famotidine 20 mg twice daily (n=204) or placebo twice daily (n=200). Patients had a final endoscopic examination at 12 weeks. The primary endpoint was the development of new ulcers in the stomach or duodenum or erosive oesophagitis at 12 weeks after randomisation. Analysis was by intention to treat, including all randomised patients who received at least one dose of study drug (famotidine or placebo). This trial is registered as an International Standard Randomised Clinical Trial, number ISRCTN96975557

2009 Lancet Controlled trial quality: predicted high

5. Review: famotidine, pizotifen, cognitive behavioural therapy, and peppermint may be effective in recurrent abdominal pain

Review: famotidine, pizotifen, cognitive behavioural therapy, and peppermint may be effective in recurrent abdominal pain Review: famotidine, pizotifen, cognitive behavioural therapy, and peppermint may be effective in recurrent abdominal pain | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: famotidine, pizotifen, cognitive behavioural therapy, and peppermint may be effective in recurrent abdominal pain Article Text

Full Text available with Trip Pro

2004 Evidence-Based Medicine (Requires free registration)

6. [FAMOTIDINE VERSUS PLACEBO IN NON ULCER DYSPEPSIA TREATMENT] (PubMed)

[FAMOTIDINE VERSUS PLACEBO IN NON ULCER DYSPEPSIA TREATMENT] BACKGROUND: Non ulcer dyspepsia is an important health problem with a very high prevalence in the general population, being its pathophysiology still unclear and its association with H. pylori highly controversial. Many trials have been carried out assessing the effects of different drugs on the symptoms in dyspeptic patients, being one of the most common the use of H2 antagonist, even though the results have shown conflicting as far (...) as efficacy is concerned. The goal of the present study is to determine the efficacy of famotidine (administered in three different regimens) as compared to placebo in relieving the symptoms of non ulcer dyspepsia.METHODS: Patients with chronic non ulcer dyspepsia were included and were selected by random in four groups; group I received famotidine 40 mg before breakfast, placebo before dinner and at bedtime; group II received famotidine 20 mg before breakfast and dinner and placebo at bedtime; group III

2002 Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru Controlled trial quality: uncertain

7. Switching the histamine H2 receptor antagonist famotidine to non-prescription status in Canada: an economic evaluation

Switching the histamine H2 receptor antagonist famotidine to non-prescription status in Canada: an economic evaluation Switching the histamine H2 receptor antagonist famotidine to non-prescription status in Canada: an economic evaluation Switching the histamine H2 receptor antagonist famotidine to non-prescription status in Canada: an economic evaluation Tasch R, Goeree R, Henke C, O'Brien B Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Histamine H2 Receptor Antagonist (H2RA) famotidine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical cohort of patients with heartburn and non-ulcer dyspepsia. Setting The practice setting was primary care. The economic

1996 NHS Economic Evaluation Database.

8. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. (PubMed)

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. Acid suppression with famotidine, a histamine H2-receptor antagonist, provides protection against gastric injury in normal subjects receiving short courses of aspirin or naproxen. The efficacy of famotidine in preventing peptic ulcers in patients receiving long-term therapy with nonsteroidal antiinflammatory drugs (NSAIDs) is not known.We studied the efficacy of two doses of famotidine (...) ulceration at 24 weeks.The cumulative incidence of gastric ulcers was 20 percent in the placebo group, 13 percent in the group of patients receiving 20 mg of famotidine twice daily (P = 0.24 for the comparison with placebo), and 8 percent in the group receiving 40 mg of famotidine twice daily (P = 0.03 for the comparison with placebo). The proportion of patients in whom duodenal ulcers developed was significantly lower with both doses of famotidine than with placebo (13 percent in the placebo group, 4

1996 NEJM Controlled trial quality: uncertain

9. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. (PubMed)

Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. To compare an over-the-counter histamine2-receptor antagonist with an antacid as gastric acid reducers.Randomized, double-blind, placebo-controlled crossover trial.Gastric secretory research laboratory in a Veterans Affairs medical center.Eighteen healthy volunteers (10 men and 8 women) aged 25 to 62 years with normal gastric acid secretion (...) rates.The subjects received the histamine2-receptor antagonist famotidine (Pepcid AC, 10 mg), calcium carbonate antacid tablets (Tums, 1000 mg), or placebo medications 1 hour after a test meal. Two identical meals were taken 2.5 and 6.0 hours after the medication was given.Intragastric pH was maintained at 4.0 by in vivo intragastric titration with 0.3N sodium bicarbonate for 10 hours (1 hour before and 9 hours after medication). Reduction in sodium bicarbonate titrant use in the 2 treatment groups

1996 JAMA Controlled trial quality: predicted high

10. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer

Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Poynard T, Lemaire M, Agostini H Authors' objectives To compare the clinical efficacy (...) of lansoprazole with the efficacies of ranitidine and famotidine. Searching The trials were identified using a MEDLINE search, a review of gastroenterology journals and from the files of two pharmaceutical companies (Houde and Takeda). Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Lansoprazole at the usual dose of 30 mg compared with famotidine (4 0mg) or ranitidine (300 mg). Participants

1995 DARE.

11. Safety and cost of rapid IV injection of famotidine in critically ill patients

Safety and cost of rapid IV injection of famotidine in critically ill patients Safety and cost of rapid IV injection of famotidine in critically ill patients Safety and cost of rapid IV injection of famotidine in critically ill patients Fish D N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The use of histamine H2-receptor antagonists (H2RAs) (specifically famotidine) administered intravenously to patients in intensive care units. Type of intervention Treatment Economic study type Cost-effectiveness analysis. Study population Patients admitted to a coronary care or ICU who received at least one dose of famotidine injection as part of their treatment. Setting Hospital. The economic study was carried out in Denver, Colorado

1995 NHS Economic Evaluation Database.

12. Continuous intravenous famotidine for haemorrhage from peptic ulcer. (PubMed)

Continuous intravenous famotidine for haemorrhage from peptic ulcer. Peptic ulcer bleeding often stops spontaneously but rebleeding may be catastrophic. Emergency surgery carries risks so safe medical therapies are needed. Since platelet function and plasma coagulation are both pH sensitive and since pepsin lyses clot at low pH the maintenance of gastric pH close to neutrality might influence rebleeding rates. Previous trials with H2 antagonists have been inadequate although a 1985 meta (...) -analysis did support an important clinical effect. We report here a large multicentre trial of famotidine in ulcer bleeding. 1005 patients admitted to one of sixty-seven hospitals in the UK or Eire with haemorrhage from peptic ulcer with endoscopic signs of oozing, black slough, fresh clot or visible vessel were randomly allocated to famotidine (10 mg bolus followed by 3.2 mg/h intravenously) or matching placebo for 72 h. This famotidine regimen had previously been shown to maintain pH near 7

1992 Lancet Controlled trial quality: uncertain